2022 American Association for Cancer Research Annual Meeting

Schedule of DCTD Presentations

DCTD-supported research will be presented at the AACR Annual Meeting   from April 8-13, 2022.

The following tables include presentations containing DCTD staff speakers and co-authors.

• Oral Presentations
• Poster Presentations
• Meet-the-Expert Presentations
• Staff Kiosk Schedule

Oral Presentations

Date/Time	Title/DCTD Speaker	ID
April 9 9:00 AM – 9:20 AM	Translation of omics predictors to clinically useful tests: Avoiding the pitfalls and paving the way to success Lisa M. McShane, PhD	ED022
April 10 1:00 – 2:00 PM	NCI Consortia Initiative: Response to Cancer Moonshot Recommendation to Establish a Network on Direct Patient Engagement - The Moonshot Biobank Helen Moore, PhD	NIH05
April 11 1:30 PM – 3:00 PM	Trust in Science Tracy Lively, PhD	FO06
April 12 9:30 AM – 10:30 AM	Meet the Editor-in-Chief, Molecular Cancer Therapeutics Beverly Teicher, PhD	Booth 2101
April 12 12:30 PM – 1:30 PM	NCI-Cancer Diagnosis Program Initiatives, Funding Opportunities and Resources for Investigators Aniruddha Ganguly, PhD, Lyndsay Harris, MD, Mickey Williams, PhD, Chris Karlovich, PhD	NIH09
April 12 2:30 PM – 3:30 PM	NCI Resource: The Frederick National Laboratory for Cancer Research and the NCI Program for Natural Product Discovery Barry O'Keefe, PhD	NIH10
April 12 5:00 PM – 6:30 PM	Breaking Down Silos; If we did it during the COVID pandemic, why not for cancer? James Doroshow, MD	FO04

Poster Presentations

Date/Time	Title/DCTD Presenter (If Applicable)	ID
April 8 12:00 PM – 1:00 PM	Inhibition of de novo and salvage pathways for dNTP synthesis enhances sensitivity to ionizing radiation in pancreatic neuroendocrine tumor cells	5430
April 8 12:00 PM – 1:00 PM	NCI’s Clinical Proteomic Tumor Analysis Consortium: A proteogenomic cancer analysis program Mehdi Mesri, PhD	6331
April 10 1:30 PM – 5:00 PM	Genomic characterization of PDX models from rare cancer patients in the NCI Patient-Derived Models Repository	80
April 11 9:00 AM – 12:30 PM	Comparative single cell transcriptome profiling of primary tumors, CTCs and metastatic sites from a bladder cancer PDX model	973
April 11 9:00 AM – 12:30 AM	LIG1 deletion predicts chemotherapy resistance, chromosomal instability, and poor prognosis in triple negative breast cancer	1010
April 11 9:00 AM – 12:30 PM	RAS-pathway inhibitors (Sotorasib, MRTX-1257, TNO-155, BI-3406) in a Complex Spheroid Combination Screen with PDMR Cell Naoko Takebe, MD, PhD	1054
April 11 9:00 AM – 12:30 PM	Screens of targeted agents combined with the ubiquitin activating enzyme inhibitor TAK-243 or the pan-Akt inhibitor ipatasertib identified combinations that are effective in patient-derived complex spheroids	1055
April 11 9:00 AM – 12:30 PM	The Clinical Genome Resource (ClinGen) somatic cancer clinical domain working group	1192
April 11 9:00 AM – 12:30 PM	A repository of PDX histology images for exploring spatial heterogeneity and cancer dynamics ;	1202
April 11 9:00 AM – 12:30 PM	Safety and efficacy of Anti-PD-L1 antibody MEDI4736 (durvalumab) in combination with capecitabine in patients with advanced solid tumors (DURVA+) Mohamad Adham Salkeni, MD	CT115
April 11 9:00 AM – 12:30 PM	Evaluation of the in vivo efficacy of the B7-H3 targeting antibody-drug conjugate (ADC) DS7300a: A report from the Pediatric Preclinical In Vivo Resting (PIVOT) program	LB061
April 11 9:00 AM – 12:30 PM	CT170 - A phase 1 / 2 study of olaparib in combination with ramucirumab in metastatic gastric and gastroesophageal junction adenocarcinoma (GEJ)	CT170
April 11 1:30 PM – 5:00 PM	Drug combination screening of Ipatasertib and Abemaciclib with other targeted agents in complex multicellular tumor spheroids from the NCI-60 and the National Cancer Institute’s Patient-Derived Models Repository	1881
April 11 1:30 PM – 5:00 PM	Quality control workflows developed for the NCI Patient-Derived Models Repository using lowpass whole genome sequencing and whole exome sequencing	1913
April 11 1:30 PM – 5:00 PM	Phase 1 study of recombinant interleukin 15 (rhIL-15) in combination with checkpoint inhibitors nivolumab and ipilimumab in subjects with refractory cancers Sarah J. Shin, MD	CT147
April 11 1:30 PM – 5:00 PM	BVD-523FB (Ulixertinib) in Patients with Tumors with BRAF Fusions, or with Non-V600E, Non-V600K BRAF Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol EAY131-Z1L	CT160
April 11 1:30 PM – 5:00 PM	Randomized phase 2 trial of sunitinib or cediranib in alveolar soft part sarcoma	CT168
April 12 9:00 AM – 12:30 PM	Integrating biospecimen science approaches in clinical assay development-PAR 22-049 Lokesh Agrawal, PhD	2791
April 12 1:30 PM – 5:00 PM	Development of an automated platform for screening patient-derived organoid models	3079
April 12 1:30 PM – 5:00 PM	Patient-derived organoid drug responses corroborate known target-drug interactions for selected anticancer agents	3091
April 12 1:30 PM – 5:00 PM	Method development for generation of PDX models from rapid autopsy samples for the NCI Patient-Derived Models Repository	3120
April 13 9:00 AM – 12:30 PM	Demethylation, DNA damage and antitumor activity of DNA methyltransferase inhibitors in models with intact and disrupted DNMT1 gene Sherry X. Yang, PhD	LB192

Meet-the-Expert Presentations – Booth 1224

Date/Time	Topic	Presenter
April 11 12:00 PM	Cooperative Human Tissue Network (CHTN) & NCI National Clinical Trials Network (NCTN) Biospecimens Available for the Cancer Research Community	Irina Lubensky, MD, CDP (presented by Aniruddha Ganguly, CDP)
April 11 2:30 PM	Opportunities for Cancer Research Support from Multiple NIH Institutes and Centers	Morgan O’Hayre, PhD, DTP
April 12 2:30 PM	High Throughput Screening with Tumor Complex Spheroids and Organoids from the NCI PDMR	Beverly Teicher, DTP
April 12 3:30 PM	NCI DCTD-Cancer Diagnosis Programs & Funding Opportunities	Aniruddha Ganguly, CDP

Staff Kiosk Schedule – Booth 1224

Date	Time	Presenter
April 10	1:00 PM – 3:00 PM	Aniruddha Ganguly, PhD Cancer Diagnosis Program
	3:00 PM – 5:00 PM	Lokesh Agrawal, PhD Cancer Diagnosis Program
April 11	9:00 AM – 11:00 AM	Morgan O’Hayre, PhD Developmental Therapeutics Program
	11:00 AM – 1:00 PM	Yali Fu, PhD Developmental Therapeutics Program
	1:00 PM – 3:00 PM	Sharad Verma, PhD Developmental Therapeutics Program
	3:00 PM – 5:00 PM	Aniruddha Ganguly, PhD Cancer Diagnosis Program Ana I. Robles, PhD Office of Cancer Clinical Proteomics Research
April 12	9:00 AM – 11:00 AM	Weiwei Chen, PhD Developmental Therapeutics Program
	11:00 AM – 1:00 PM	Connie Sommers, PhD Developmental Therapeutics Program
	1:00 PM – 3:00 PM	Sundar Venkatachalam, PhD Developmental Therapeutics Program
	3:00 PM – 5:00 PM	Marc S. Ernstoff, MD
April 13	9:00 AM – 12:00 PM	Aniruddha Ganguly, PhD